ClinicalTrials.gg
CompletedNCT05035082REALYSEUpdated Aug 10, 2026Results posted

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

A Phase 4 interventional study of semaglutide and oral glucose-lowering medications (commercially available) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,018
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
17th of 163
1,018 · median 104
Started
2021
with 9 others
Phase 4
40 of 163
17 open now
Registered
89th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 10 that started in 2021, is one of 40 in phase 4, and was the 89th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 1 year. Participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. In addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria

  • Treatment with metformin as monotherapy prior to eligibility assessment that has failed to result in adequate glycemic control at the discretion of the investigator or treatment provider. However, prior short-term treatment with an oral glucose lowering agent or insulin for up to 14 consecutive days in addition to metformin is allowed if discontinued prior to screening.
  • Current member of a health plan which includes pharmacy benefits.
  • greater than or equal to 7% within last 90 days prior to the day of screening or to be taken before randomization.
  • Further intensification with an additional glucose-lowering oral agent including oral semaglutide is indicated according to approved prescribing information to achieve glycemic target at the discretion of the treatment provider.

Key exclusion criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using .
  • Any disorder which in the investigator's or treatment provider's opinion might jeopardize patient's safety.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,018 participants (actual)

Study arms

  • Experimental
    oral semaglutide

    All participants are given tablets used in addition to metformin.

    Drug: semaglutide

  • Active comparator
    other oral glucose lowering medication

    All participants are given tablets used in addition to metformin.

    Drug: oral glucose-lowering medications (commercially available)

Interventions

  • Oral administration The doctor will give a prescription for the medicine and tell how to take it.

  • Drugoral glucose-lowering medications (commercially available)

    Oral administration The doctor will give a prescription for the medicine and tell how to take it.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c in percentage from week 0 to year 1 is presented

    Time frame: Week 0, year 1

Secondary outcomes

  1. Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) (Yes /No)

    Participants achieving HbA1c \< 7.0% (Yes /No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% and 'No' defines participants who did not achieve HbA1c \< 7.0 %.

    Time frame: At year 1

  2. Participants Achieving HbA1c Less Than or Equal to (≤) 6.5% (Yes/No)

    Participants achieving HbA1c ≤ 6.5% (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c ≤ 6.5% and 'No' defines participants who did not achieve HbA1c ≤ 6.5%.

    Time frame: At year 1

  3. Participants Achieving HbA1c <7.0% or at Least 1.0%-Point Reduction in HbA1c (Yes/No)

    Participants achieving HbA1c \< 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c and 'No' defines participants who did not achieve HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c.

    Time frame: From Week 0 to year 1

  4. Participants Achieving Greater Than or Equal to (≥) 5% Reduction in Body Weight (Yes/No)

    Participants achieving ≥ 5% reduction in body weight (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved ≥ 5% reduction in body weight and 'No' defines participants who did not achieve ≥ 5% reduction in body weight.

    Time frame: From week 0 to year 1

  5. Participant Achieving Individualized HbA1c Target Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria (Yes/No)

    Participants achieving individualized HbA1c target per HEDIS criteria (\< 8.0% if age ≥ 65 years or with defined comorbidities or otherwise \< 7.0%) (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved individualized HbA1c target per HEDIS criteria and 'No' defines participants who did not achieve individualized HbA1c target per HEDIS criteria.

    Time frame: At year 1

  6. Participant Achieving HbA1c ≤ Treatment Provider Defined Individualized Target (Yes/No)

    Participant achieving HbA1c ≤ treatment provider defined individualized target (Yes/No) at year 1 is presented. 'Yes' defines participant who achieved HbA1c ≤ treatment provider defined individualized target and 'No' defines participant who did not achieve HbA1c ≤ treatment provider defined individualized target.

    Time frame: At year 1

  7. Relative Change in Body Weight (%)

    Relative change in body weight from week 0 to year 1 is presented.

    Time frame: Week 0, year 1

  8. Change in Body Weight (Lbs)

    Change in body weight in pounds (lbs) from week 0 to year 1 is presented.

    Time frame: Week 0, year 1

  9. Time to Treatment Intensification (add-on) or Change (Switch) in Terms of Events

    Time to treatment intensification (add-on) or change (switch) in terms of events from week 0 to year 1 is presented.

    Time frame: From week 0 to year 1

  10. Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score

    DTSQc relative treatment satisfaction total score measured at year 1 is presented. DTSQc are used to evaluate patient satisfaction with treatment. The measure consists of 8 items, 6 of which assess treatment satisfaction. Scores from the 6 treatment satisfaction items are summed to a total treatment satisfaction score, which ranges from -18 (much less satisfied) to +18 (much more satisfied).

    Time frame: At year 1

07

Results

Posted Aug 10, 2026

Participant flow

The trial was conducted at 25 sites in the United States. One participant is counted in 'Completed' and not in 'Death in Reason for Not Completed' in Participant Flow as they died after completing the study and hence, not counted as non-completer.

Participant flow — Overall Study
MilestoneOral SemaglutideOther Oral Glucose-lowering Medication
Started509509
Full analysis set509509
Safety analysis set500492
Completed449448
Not completed6061
Withdrew: Withdrawal by subject2426
Withdrew: Lost to follow-up2930
Withdrew: Death31
Withdrew: Site closure01
Withdrew: Protocol specified withdrawal criterion met43

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c in percentage from week 0 to year 1 is presented

Time frame:
Week 0, year 1
Reported as:
Mean · Percentage change in HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage change in HbA1cOral SemaglutideOther Oral Glucose-lowering Medication
Change in Glycated Haemoglobin (HbA1c)-1.20 ± 1.463-0.99 ± 1.516
Statistical analysis
  • Oral Semaglutide vs Other Oral Glucose-lowering Medication · ANCOVA · p = 0.0180 · Treatment difference: -0.24 · 95% CI -0.44 to -0.04
SecondaryParticipants Achieving HbA1c Less Than (<) 7.0 Percentage (%) (Yes /No)

Participants achieving HbA1c \< 7.0% (Yes /No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% and 'No' defines participants who did not achieve HbA1c \< 7.0 %.

Time frame:
At year 1
Reported as:
Count of participants · Participants
Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) (Yes /No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes190133
No136160
SecondaryParticipants Achieving HbA1c Less Than or Equal to (≤) 6.5% (Yes/No)

Participants achieving HbA1c ≤ 6.5% (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c ≤ 6.5% and 'No' defines participants who did not achieve HbA1c ≤ 6.5%.

Time frame:
At year 1
Reported as:
Count of participants · Participants
Participants Achieving HbA1c Less Than or Equal to (≤) 6.5% (Yes/No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes12768
No199225
SecondaryParticipants Achieving HbA1c <7.0% or at Least 1.0%-Point Reduction in HbA1c (Yes/No)

Participants achieving HbA1c \< 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c and 'No' defines participants who did not achieve HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c.

Time frame:
From Week 0 to year 1
Reported as:
Count of participants · Participants
Participants Achieving HbA1c <7.0% or at Least 1.0%-Point Reduction in HbA1c (Yes/No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes239180
No87113
SecondaryParticipants Achieving Greater Than or Equal to (≥) 5% Reduction in Body Weight (Yes/No)

Participants achieving ≥ 5% reduction in body weight (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved ≥ 5% reduction in body weight and 'No' defines participants who did not achieve ≥ 5% reduction in body weight.

Time frame:
From week 0 to year 1
Reported as:
Count of participants · Participants
Participants Achieving Greater Than or Equal to (≥) 5% Reduction in Body Weight (Yes/No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes11083
No188177
SecondaryParticipant Achieving Individualized HbA1c Target Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria (Yes/No)

Participants achieving individualized HbA1c target per HEDIS criteria (\< 8.0% if age ≥ 65 years or with defined comorbidities or otherwise \< 7.0%) (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved individualized HbA1c target per HEDIS criteria and 'No' defines participants who did not achieve individualized HbA1c target per HEDIS criteria.

Time frame:
At year 1
Reported as:
Count of participants · Participants
Participant Achieving Individualized HbA1c Target Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria (Yes/No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes222171
No104122
SecondaryParticipant Achieving HbA1c ≤ Treatment Provider Defined Individualized Target (Yes/No)

Participant achieving HbA1c ≤ treatment provider defined individualized target (Yes/No) at year 1 is presented. 'Yes' defines participant who achieved HbA1c ≤ treatment provider defined individualized target and 'No' defines participant who did not achieve HbA1c ≤ treatment provider defined individualized target.

Time frame:
At year 1
Reported as:
Count of participants · Participants
Participant Achieving HbA1c ≤ Treatment Provider Defined Individualized Target (Yes/No)
ParticipantsOral SemaglutideOther Oral Glucose-lowering Medication
Yes179118
No147175
SecondaryRelative Change in Body Weight (%)

Relative change in body weight from week 0 to year 1 is presented.

Time frame:
Week 0, year 1
Reported as:
Mean · Percentage change in body weight
Relative Change in Body Weight (%)
Percentage change in body weightOral SemaglutideOther Oral Glucose-lowering Medication
Relative Change in Body Weight (%)-4.00 ± 6.26-3.53 ± 6.49
SecondaryChange in Body Weight (Lbs)

Change in body weight in pounds (lbs) from week 0 to year 1 is presented.

Time frame:
Week 0, year 1
Reported as:
Mean · Lbs
Change in Body Weight (Lbs)
LbsOral SemaglutideOther Oral Glucose-lowering Medication
Change in Body Weight (Lbs)-8.68 ± 14.23-7.75 ± 15.61
SecondaryTime to Treatment Intensification (add-on) or Change (Switch) in Terms of Events

Time to treatment intensification (add-on) or change (switch) in terms of events from week 0 to year 1 is presented.

Time frame:
From week 0 to year 1
Reported as:
Number · Events
Time to Treatment Intensification (add-on) or Change (Switch) in Terms of Events
EventsOral SemaglutideOther Oral Glucose-lowering Medication
Time to Treatment Intensification (add-on) or Change (Switch) in Terms of Events69109
SecondaryDiabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score

DTSQc relative treatment satisfaction total score measured at year 1 is presented. DTSQc are used to evaluate patient satisfaction with treatment. The measure consists of 8 items, 6 of which assess treatment satisfaction. Scores from the 6 treatment satisfaction items are summed to a total treatment satisfaction score, which ranges from -18 (much less satisfied) to +18 (much more satisfied).

Time frame:
At year 1
Reported as:
Mean · Score on a scale
Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score
Score on a scaleOral SemaglutideOther Oral Glucose-lowering Medication
Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score12.28 ± 6.7312.22 ± 6.18

Adverse events

Collected over From week 0 to week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Semaglutide3/500 (0.6%)51/500 (10.2%)81/500 (16.2%)
Other Oral Glucose-lowering Medication2/492 (0.4%)55/492 (11.2%)46/492 (9.3%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventOral SemaglutideOther Oral Glucose-lowering Medication
PneumoniaInfections and infestations2/5005/492
SepsisInfections and infestations2/5005/492
SyncopeNervous system disorders0/5005/492
FallInjury, poisoning and procedural complications4/5003/492
Chest painGeneral disorders2/5003/492
NauseaGastrointestinal disorders3/5003/492
Non-cardiac chest painGeneral disorders0/5003/492
Acute kidney injuryRenal and urinary disorders2/5002/492
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/5002/492
Atrial fibrillationCardiac disorders1/5002/492
Most frequent other events
Most frequent other events
EventOral SemaglutideOther Oral Glucose-lowering Medication
COVID-19Infections and infestations44/50037/492
NauseaGastrointestinal disorders38/50010/492

Baseline characteristics

Full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(Years)Oral SemaglutideOther Oral Glucose-lowering MedicationTotal
Mean59.6 ± 11.959.8 ± 12.059.7 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Oral SemaglutideOther Oral Glucose-lowering MedicationTotal
Female231237468
Male278272550
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral SemaglutideOther Oral Glucose-lowering MedicationTotal
White373366739
Black or African American6568133
Asian443680
Other213960
Missing Race606
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral SemaglutideOther Oral Glucose-lowering MedicationTotal
Hispanic or Latino91102193
Non-Hispanic or Non-Latino408404812
Missing Ethnicity10313
08

Study locations

25 sites
  • Stewart Medical Group
    Alhambra, California 91801, United States
  • FDRC
    Costa Mesa, California 92627, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • Raincross Medical Group
    Riverside, California 92506, United States
  • Reyes Clinical Research, Inc
    Miami, Florida 33175, United States
  • DC Research Works
    Marietta, Georgia 30060, United States
  • Urban Family Practice Assoc
    Marietta, Georgia 30067, United States
  • Macoupin Research Group
    Gillespie, Illinois 62033, United States
  • UnityPoint Health-Diabetes Care Center
    Peoria, Illinois 61603, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Kernodle Clin Dpt-Pvt Diagnost
    Burlington, North Carolina 27215, United States
  • OnSite Clinical Solutions, LLC_Charlotte
    Charlotte, North Carolina 28277, United States
  • WakeMed Garner Hlthplx
    Garner, North Carolina 27529, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Valley Weight Loss Clinic
    Fargo, North Dakota 58104, United States
  • Diab & Endo Assoc of Stark Co
    Canton, Ohio 44718, United States
  • Central Ohio Clinical Research LLC
    Columbus, Ohio 43213, United States
  • Jefferson Endocrinology Assocs
    Philadelphia, Pennsylvania 19107-6810, United States
  • Tristar Clin Investigations, PC
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians_Pittsburgh
    Pittsburgh, Pennsylvania 15236, United States
  • AnMed Health IMA
    Anderson, South Carolina 29621, United States
  • Baylor Scott & White Res Inst
    Dallas, Texas 75246, United States
  • Hill Country Medical Associates
    New Braunfels, Texas 78130, United States
  • DCT-Stone Oak
    San Antonio, Texas 78258, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2025, 45 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 45 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 5, 2021
StartActual
Sep 1, 2021
Primary completionActual
Jun 18, 2025
CompletionActual
Jun 18, 2025
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05035082
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Sep 1, 2021
Primary completion
Jun 18, 2025
Completion
Jun 18, 2025
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion